Treatment of achalasia: Botulinum toxin injection vs. pneumatic balloon dilation. A prospective study with long-term follow-up

Endoscopy

Volumn 33, Issue 12, 2001, Pages 1007-1017

  Allescher, H D ^a   Storr, M ^a   Seige, M ^a   Gonzales Donoso, R ^a   Ott, R ^a   Born, P ^a   Frimberger, E ^a   Weigert, N ^a   Stier, A ^b   Kurjak, M ^a   Rosch T ^a   Classen, M ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN A; PLACEBO;

ADULT; AGED; ARTICLE; BALLOON DILATATION; BODY WEIGHT; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG SAFETY; ELDERLY CARE; ESOPHAGUS ACHALASIA; ESOPHAGUS MANOMETRY; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; INJECTION; LONG TERM CARE; LOWER ESOPHAGUS SPHINCTER PRESSURE; MALE; OUTPATIENT CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECURRENT DISEASE; RELAPSE; SHORT COURSE THERAPY; STATISTICAL ANALYSIS; SYMPTOM; THORAX PAIN; TREATMENT FAILURE; TREATMENT OUTCOME;

ACTUARIAL ANALYSIS; ADULT; AGED; ANTI-DYSKINESIA AGENTS; BALLOON DILATATION; BOTULINUM TOXINS; COST-BENEFIT ANALYSIS; ESOPHAGEAL ACHALASIA; FEMALE; HUMANS; INJECTIONS; MALE; MANOMETRY; MIDDLE AGED; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 0035203242     PISSN: 0013726X     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2001-18935     Document Type: Article

References (51)

1. The site of denervation in achalasia
2. "Cardiospasm" in achalasia: Demonstration of hypersensitivity of the lower esophageal sphincter
3. Achalasia, diffuse esophageal spasm and related motility disorders
4. Lack of vasoactive intestinal polypeptide in nerves in esophageal achalasia
5. Nitric oxide mediating NANC inhibition in opossum lower esophageal sphincter
6. The role of the L-arginine nitric oxide pathway in relaxation of the lower esophageal sphincter
7. Treatment of achalasia with pneumatic dilatation
8. Treatment of achalasia and related motor disorders
9. Pneumatic dilatation in achalasia
10. Complications during pneumatic dilatation for achalasia or diffuse esophageal spasm. Analysis of risk factors, early clinical characteristics and outcome
11. The role of nifedipine therapy in achalasia: Results of a randomized, double-blind, placebo-controlled study
12. The surgical management of motility disorders
13. Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25
14. Therapeutic uses of botulinum toxin
15. Effects of intrasphincteric botulinum toxin on the lower esophageal sphincter in piglets
16. Botulinum toxin for achalasia
17. Treatment of achalasia with intrasphincteric injection of botulinum toxin. A pilot trial
18. Intrasphincteric botulinum toxin for the treatment of achalasia
19. Treatment of achalasia in Chagas' disease with botulinum toxin
20. Treatment of symptomatic nonachalasia esophageal motor disorders with botulinum toxin injection at the lower esophageal sphincter
21. Treatment of symptomatic diffuse esophageal spasm by injection of Botulinum toxin (BTX)
22. Apamin distinguishes two types of relaxation mediated by enteric nerves in the guinea-pig gastrointestinal tract
23. Double blind placebo controlled study on the effect of the nitric oxide donor molsidomin and the 5-HT3 antagonist ondansetron on human esophageal motility
24. Balloon dilatation in achalasia: A new dilatator
25. An overview over the statistical methods for multiple failure time data in clinical trials
26. Symptomatic improvement in achalasia after botulinum toxin injection of the lower esophageal sphincter
27. Use of botulinum A toxin in achalasia
28. Endoscopic intrasphincteric injection of botulinum toxin for the treatment of achalasia
29. Intrasphincteric injection of botulinum toxin for treating achalasia in children
30. Perendoscopic injection of botulinum toxin is effective in achalasia after failure of myotomy or pneumatic dilation
31. Controlled trial of botulinum toxin injection versus placebo and pneumatic dilation in achalasia
32. Botulinum toxin for achalasia: Long-term outcome and predictors of response
33. Achalasia: Outcome of patients treated by intrasphincteric injection of botulinum toxin
34. Comparison of two different formulations of botulinum toxin A for the treatment of esophageal achalasia. The Gismad Achalasia Study Group
35. Randomized prospective trial of 50 vs. 100 IU BOTOX for achalasia - Long-term-follow up
36. A multicenter randomised study of intrasphincteric botulinum toxin in patients with esophageal achalasia. GISMAD Achalasia Study Group
37. Botulinum toxin injections for achalasia symptoms can approximate the short term efficacy of a single pneumatic dilatation: A survival analysis approach
38. Use of botulinum toxin as a diagnostic/therapeutic trial to help clarify an indication for definitive therapy in patients with achalasia
39. Esophageal achalasia: Intrasphincteric injection of botulinum toxin A versus balloon dilatation
40. Esophageal botulinum toxin injection in high risk achalasia patients: A prospective trial
41. Predictors of outcome in patients with achalasia treated by pneumatic dilatation
42. Pneumatic dilatation or esophagomyotomy treatment for idiopathic achalasia: Clinical outcomes and cost analysis
43. Interim analysis of a randomized trial of Witzel pneumatic dilatation vs. intrasphincteric injection of botulinum toxin for achalasia
44. Botulinum toxin is effective in the short-term treatment of esophageal achalasia. Preliminary results of a randomized trial
45. Intrasphincteric injection of botulinum toxin is effective in long-term treatment of esophageal achalasia
46. Current therapies for achalasia: Comparison and efficacy
47. Long-term results in surgically managed esophageal achalasia
48. Botulinum toxin versus pneumatic dilatation in the treatment of achalasia: A randomised trial
49. Intrasphincteric botulinum toxin versus pneumatic dilatation for achalasia: A cost minimization analysis
50. Gastrointestinal uses of botulinum toxin
51. Esophageal pharmacology and treatment of primary motility disorders